메뉴 건너뛰기




Volumn 109, Issue 3, 2013, Pages 538-544

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENVATINIB; PACLITAXEL;

EID: 84883166619     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.374     Document Type: Article
Times cited : (39)

References (31)
  • 1
    • 0035142923 scopus 로고    scopus 로고
    • Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer
    • Baillie R, Carlile J, Pendleton N, Schor AM (2001) Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J Clin Pathol 54: 116-120.
    • (2001) J Clin Pathol , vol.54 , pp. 116-120
    • Baillie, R.1    Carlile, J.2    Pendleton, N.3    Schor, A.M.4
  • 2
    • 47949099628 scopus 로고    scopus 로고
    • Modes of resistance to anti-angiogenic therapy
    • Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
    • (2008) Nat Rev Cancer , vol.8 , pp. 592-603
    • Bergers, G.1    Hanahan, D.2
  • 4
    • 84883186017 scopus 로고    scopus 로고
    • Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS http://ctep.cancer.gov Accessed 2012
    • Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS http://ctep.cancer.gov (2006) http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf. Accessed (2012).
    • (2006)
  • 5
    • 0038363443 scopus 로고    scopus 로고
    • Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2
    • Cao R, Bråkenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y (2003) Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9: 604-613.
    • (2003) Nat Med , vol.9 , pp. 604-613
    • Cao, R.1    Bråkenhielm, E.2    Pawliuk, R.3    Wariaro, D.4    Post, M.J.5    Wahlberg, E.6    Leboulch, P.7    Cao, Y.8
  • 6
    • 77950402591 scopus 로고    scopus 로고
    • Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer
    • Donnem T, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM (2010) Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann Oncol 21: 223-231.
    • (2010) Ann Oncol , vol.21 , pp. 223-231
    • Donnem, T.1    Al-Saad, S.2    Al-Shibli, K.3    Busund, L.T.4    Bremnes, R.M.5
  • 7
    • 58149190795 scopus 로고    scopus 로고
    • Pathways mediating resistance to vascular endothelial growth factor-targeted therapy
    • Ellis LM, Hicklin DJ (2008) Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 14: 6371-6375.
    • (2008) Clin Cancer Res , vol.14 , pp. 6371-6375
    • Ellis, L.M.1    Hicklin, D.J.2
  • 8
    • 4143136640 scopus 로고    scopus 로고
    • Vascular endothelial growth factor: Basic science and clinical progress
    • Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
    • (2004) Endocr Rev , vol.25 , pp. 581-611
    • Ferrara, N.1
  • 10
    • 0036849944 scopus 로고    scopus 로고
    • The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer
    • Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, Yoshino I, Hara N (2002) The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res 8: 3480-3486.
    • (2002) Clin Cancer Res , vol.8 , pp. 3480-3486
    • Inoshima, N.1    Nakanishi, Y.2    Minami, T.3    Izumi, M.4    Takayama, K.5    Yoshino, I.6    Hara, N.7
  • 13
    • 84856462493 scopus 로고    scopus 로고
    • Adding to the mix: Fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer
    • Kono SA, Heasley LE, Doebele RC, Camidge DR (2012) Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets 12: 107-123.
    • (2012) Curr Cancer Drug Targets , vol.12 , pp. 107-123
    • Kono, S.A.1    Heasley, L.E.2    Doebele, R.C.3    Camidge, D.R.4
  • 14
    • 37349105704 scopus 로고    scopus 로고
    • E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
    • Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M (2008a) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122: 664-671.
    • (2008) Int J Cancer , vol.122 , pp. 664-671
    • Matsui, J.1    Yamamoto, Y.2    Funahashi, Y.3    Tsuruoka, A.4    Watanabe, T.5    Wakabayashi, T.6    Uenaka, T.7    Asada, M.8
  • 15
    • 53049085556 scopus 로고    scopus 로고
    • Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumour MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
    • Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (2008b) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumour MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459-5465.
    • (2008) Clin Cancer Res , vol.14 , pp. 5459-5465
    • Matsui, J.1    Funahashi, Y.2    Uenaka, T.3    Watanabe, T.4    Tsuruoka, A.5    Asada, M.6
  • 16
    • 44249086425 scopus 로고    scopus 로고
    • Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship
    • Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594.
    • (2008) Mayo Clin Proc , vol.83 , pp. 584-594
    • Molina, J.R.1    Yang, P.2    Cassivi, S.D.3    Schild, S.E.4    Adjei, A.A.5
  • 17
    • 3042855669 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for nonsmall cell lung cancer
    • Nakashima T, Huang CL, Liu D, Kameyama K, Masuya D, Ueno M, Haba R, Yokomise H (2004) Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for nonsmall cell lung cancer. Med Sci Monit 10: BR157-BR165.
    • (2004) Med Sci Monit , vol.10
    • Nakashima, T.1    Huang, C.L.2    Liu, D.3    Kameyama, K.4    Masuya, D.5    Ueno, M.6    Haba, R.7    Yokomise, H.8
  • 19
    • 53749097825 scopus 로고    scopus 로고
    • Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials
    • NSCLC Meta-Analyses Collaborative Group
    • NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26: 4617-4625.
    • (2008) J Clin Oncol , vol.26 , pp. 4617-4625
  • 22
    • 33847276516 scopus 로고    scopus 로고
    • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
    • Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323.
    • (2007) Ann Oncol , vol.18 , pp. 317-323
    • Ohe, Y.1    Ohashi, Y.2    Kubota, K.3    Tamura, T.4    Nakagawa, K.5    Negoro, S.6    Nishiwaki, Y.7    Saijo, N.8    Ariyoshi, Y.9    Fukuoka, M.10
  • 25
    • 84857407325 scopus 로고    scopus 로고
    • Fibroblast growth factor signaling in non-smallcell lung cancer
    • Semrad TJ, Mack PC (2012) Fibroblast growth factor signaling in non-smallcell lung cancer. Clin Lung Cancer 13: 90-95.
    • (2012) Clin Lung Cancer , vol.13 , pp. 90-95
    • Semrad, T.J.1    MacK, P.C.2
  • 27
    • 79960037492 scopus 로고    scopus 로고
    • Tyrosine kinase receptor Flt/VEGFR family: Its characterization related to angiogenesis and cancer
    • Shibuya M (2010) Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer. Genes Cancer 1: 1119-1123.
    • (2010) Genes Cancer , vol.1 , pp. 1119-1123
    • Shibuya, M.1
  • 28
    • 0029417264 scopus 로고
    • Phase i study of paclitaxel by three-hour infusion: Hypotension just after infusion is one of the major dose-limiting toxicities
    • Tamura T, Sasaki Y, Nishiwaki Y, Saijo N (1995) Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 86: 1203-1209.
    • (1995) Jpn J Cancer Res , vol.86 , pp. 1203-1209
    • Tamura, T.1    Sasaki, Y.2    Nishiwaki, Y.3    Saijo, N.4
  • 30
    • 75149170979 scopus 로고    scopus 로고
    • Fibroblast growth factor signalling: From development to cancer
    • Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129.
    • (2010) Nat Rev Cancer , vol.10 , pp. 116-129
    • Turner, N.1    Grose, R.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.